Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 3/20 | 0.60 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | CCR1 | P32246 | 2/20 | 0.49 |
| ▸ | CCR3 | P51677 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7104448 | 0.91 | SIGMAR1 (0.65) | OPRL1SIGMAR1POLBKCNA3DRD2 | |
| SCHEMBL5888817 | 0.85 | DRD2 (0.62) | OPRL1DRD2OPRM1CCR1CCR3 | |
| SCHEMBL7244281 | 0.84 | KCNA3 (0.63) | OPRL1SIGMAR1POLBKCNA3DRD2 | |
| SCHEMBL7104660 | 0.84 | OPRL1 (0.61) | OPRL1SIGMAR1POLBKCNA3DRD2 | |
| SCHEMBL7109502 | 0.81 | DRD2 (0.54) | OPRL1DRD2OPRM1CCR1CCR3 | |
| SCHEMBL7110312 | 0.81 | DRD2 (0.64) | OPRL1SIGMAR1POLBKCNA3DRD2 | |
| SCHEMBL7104650 | 0.80 | OPRL1 (0.65) | OPRL1SIGMAR1DRD2OPRM1CCR1 | |
| SCHEMBL6967697 | 0.80 | OPRL1 (0.52) | OPRL1SIGMAR1DRD2OPRM1CCR1 | |
| SCHEMBL10697451 | 0.79 | SIGMAR1 (0.65) | OPRL1SIGMAR1POLBKCNA3DRD2 | |
| SCHEMBL24489451 | 0.79 | OPRL1 (0.65) | OPRL1SIGMAR1POLBKCNA3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | BIGGE CHRISTOPHER F (US) | 2003-06-05 | — | — | US | claimed |
| EP-0869791-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-04-28 | — | — | EP | claimed |
| EP-0869791-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | claimed |
| WO-1997023214-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | claimed |
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | BIGGE CHRISTOPHER F (US) | 2003-06-05 | — | — | US | disclosed |
| US-6448270-B1 | BICYCLIC HETEROARYL ACETYLENES; NEUROPROTECTIVE AGENTS; STROKE, CEREBRAL ISCHEMIA, CENTRAL NERVOUS SYSTEM TRAUMA, HYPOGLYCEMIA, ANXIETY, CONVULSIONS, AMINOGLYCOSIDE ANTIBIOTIC INDUCED HEARING LOSS, MIGRAINES, CHRONIC PAIN, GLAUCOMA | WARNER-LAMBERT COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-6130234-A | 4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists | WARNER-LAMBERT COMPANY (US) | 2000-10-10 | — | — | US | disclosed |
| EP-0869791-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0869791-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997023214-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105133-A1 | 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists | GRIN3B, OPRM1, GRIN3A | OPRL1 32/4885SIGMAR1 774/4885POLB 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.